Benitec Biopharma (BNTC) Amortization of Deferred Charges (2019 - 2025)
Benitec Biopharma has reported Amortization of Deferred Charges over the past 7 years, most recently at $106000.0 for Q4 2025.
- Quarterly results put Amortization of Deferred Charges at $106000.0 for Q4 2025, up 58.21% from a year ago — trailing twelve months through Dec 2025 was $408000.0 (up 55.13% YoY), and the annual figure for FY2025 was $330000.0, up 28.91%.
- Amortization of Deferred Charges reached $106000.0 in Q4 2025 per BNTC's latest filing, up from $105000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $106000.0 in Q4 2025 and bottomed at $48000.0 in Q1 2021.
- Median Amortization of Deferred Charges over the past 5 years was $63000.0 (2023), compared with a mean of $68250.0.
- The largest annual shift saw Amortization of Deferred Charges grew 1.67% in 2023 before it surged 60.0% in 2025.
- Over 5 years, Amortization of Deferred Charges stood at $58000.0 in 2021, then grew by 5.17% to $61000.0 in 2022, then rose by 3.28% to $63000.0 in 2023, then rose by 6.35% to $67000.0 in 2024, then surged by 58.21% to $106000.0 in 2025.
- Business Quant data shows Amortization of Deferred Charges for BNTC at $106000.0 in Q4 2025, $105000.0 in Q3 2025, and $104000.0 in Q2 2025.